查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1723659

稀少肾臟疾病市场:各标的适应症，各分子类型，生技药品类别，各给药途径，治疗类别，主要各地区，主要医药品开发各企业，预测销售额:2040年为止的产业趋势与全球预测

Rare Kidney Diseases Market by Target Disease Indications, Type of Biologics, Route of Administration, Type of Therapy, Key Geographical Regions, Leading Drug Developers and Sales Forecast: Industry Trends and Global Forecasts, Till 2040
出版日期: | 出版商: Roots Analysis | 英文 338 Pages | 商品交期: 最快1-2个工作天内

价格

罕见肾臟病市场

2024 年全球罕见肾臟病市场规模为 22 亿美元。目前该市场规模为 28 亿美元，预计到 2035 年将达到 116 亿美元，预测期内复合年增长率为 15.2%。

罕见肾臟病市场机会分布在以下领域：

目标适应症

  • 非典型溶血性尿毒症综合症
  • 法布瑞氏症
  • 局部节段性肾丝球硬化症
  • 免疫球蛋白A肾病
  • 狼疮性肾炎
  • 其他

分子类型

  • 生物製剂
  • 小分子

生物製剂类型

  • 酶
  • 激素
  • 单株抗体
  • 蛋白质

给药途径给药方式

  • 静脉注射
  • 口服
  • 皮下注射

治疗类型

  • 单药治疗
  • 合併治疗

主要地区

  • 北美
  • 欧洲
  • 亚太地区

罕见肾臟病市场：成长与趋势

肾臟疾病包括多种疾病，这些疾病会阻碍肾臟有效过滤血液中废物和多余液体的自然能力。这些疾病也会损害肾臟调节血压和维持体液平衡的整体功能。肾臟疾病尤其难以诊断，因为它们在早期通常没有症状。然而，随着废物在体内积聚，可能会出现高血压、贫血、营养不良和神经系统疾病等症状。根据美国疾病管制与预防中心的数据，到2024年，美国将有约3,550万人罹患肾臟疾病，占总人口的近14%。罕见肾臟疾病是这些疾病中的一个亚类，在全球范围内仅影响一小部分人。根据 "孤儿药法案" ，在美国，如果一种疾病影响的人数少于20万人，则将其归类为罕见疾病。然而，在欧盟，罕见疾病的定义是每10,000个欧洲人中约有5人受到影响的疾病。

罕见肾臟疾病主要影响肾臟的过滤装置（称为肾小球），导致蛋白质物质和血液渗漏到尿液中。这些疾病可能是先天性的、后天性的或遗传性的，因此很难确定用于诊断和治疗的特定生物标记。如果不及时干预，罕见肾臟疾病往往会导致肾衰竭，需要透析或移植。值得注意的是，至少五分之三的儿童和九分之一的成人肾臟病患者会因罕见慢性肾臟病导致肾衰竭。为了应对这些挑战，罕见肾臟病的诊断和治疗已取得显着进展。精准医疗，例如基因组定序和个人化治疗，使得这些疾病的标靶治疗成为可能。此外，大数据和机器学习的整合也为众多药物开发商和研究人员提供了帮助，帮助他们改进临床试验的患者招募，并识别出用于个人化治疗的精准尿液生物标记。

Rare Kidney Diseases Market-IMG1

此外，公共和私营部门的大量投资正在加速该领域的研发。目前，药物开发商已拨出超过120亿美元用于罕见肾臟病的研究和治疗开发。此外，随着对高效诊断和治疗的日益重视，罕见肾臟病药物/疗法市场有望在未来几年实现强劲成长，并为利害关係人带来重大机会。

罕见肾臟病市场：关键洞察

本报告深入探讨了罕见肾臟病市场的现状，并识别了该行业的潜在成长机会。报告的主要发现包括：

  • 超过 70% 的罕见肾臟病药物/疗法正处于临床开发阶段。值得注意的是，大多数针对免疫球蛋白A肾病和狼疮性肾炎的药物/疗法正在研究中。
Rare Kidney Diseases Market-IMG2
  • 过去各利益相关者之间建立的合作伙伴关係数量表明，各方对该领域的兴趣日益浓厚；事实上，65% 的交易是在过去三年内达成的。
  • 多家投资者已经意识到该领域的机遇，并透过多轮融资投入了大量资金，其中 45% 的投资是透过二次发行进行的。
  • 目前，近 40% 的罕见肾臟病药物正处于临床开发的 II 期阶段。
Rare Kidney Diseases Market-IMG3
  • 预计到2035年，罕见肾臟病市场的复合年增长率将达到15%，其中北美市场预计将占据大部分市场占有率（约70%）。
Rare Kidney Diseases Market-IMG4
  • 现在，单株抗体垄断市场做着，尤其是口服给药2035年之前与占市场大半部分预料。

罕见肾臟病市场：关键细分市场

根据目标适应症，全球罕见肾臟病市场细分为非典型溶血性尿毒症症候群、法布瑞氏症、局部节段性肾丝球硬化症、免疫球蛋白A肾病变、狼疮性肾炎等。目前，由于患者群体和医疗保健专业人员对该疾病的危害性认识不断提高，狼疮性肾炎占据罕见肾臟疾病市场的大部分占有率。

依分子类型，全球市场细分为小分子和生物製剂。在这些类型中，小分子市场在当前整体市场中占有最大占有率。然而，值得注意的是，生物製剂已成为一种有前景的替代方案，可以靶向与罕见肾臟疾病相关的潜在生物学途径，因此预计未来几年将占据更大的市场占有率。

依生物製剂类型，全球市场规模可细分为酵素、荷尔蒙、单株抗体和蛋白质。值得注意的是，单株抗体目前占据市场主导地位。此外，由于其在治疗罕见肾臟疾病方面的精准性已被证实，这一趋势未来不太可能改变。

依给药途径，全球市场可细分为静脉注射、口服和皮下注射。目前，口服给药途径预计将占据罕见肾臟疾病市场的大多数占有率，因为与其他途径相比，它是一种非侵入性途径，并且能够提高患者的依从性。然而，值得一提的是，预计这一趋势在预测期内将有所改变，预计未来几年皮下给药途径将占据整体市场的更大占有率。

依治疗类型，全球罕见肾臟病市场可细分为单药治疗及合併治疗。目前，单药治疗占据整体市场的最大占有率。然而，在预测期内，联合疗法市场可能会以相对较高的复合年增长率成长。

依主要地区划分，市场分为北美、欧洲和亚太地区。目前，北美占据最大市场占有率。然而，预测期内亚太地区市场预计将以更快的速度成长，因为在中国、日本、韩国和印度等亚洲国家，罕见肾臟病的盛行率正在上升，因此该地区需要更有效的治疗管理系统。

报告解答的关键问题

  • 目前有多少家公司进入该市场？
  • 该市场的主要公司
  • 可能影响该市场发展的因素
  • 当前与未来的市场规模
  • 该市场的复合年增长率
  • 当前和未来的市场机会可能如何在主要细分市场中分配？
  • 市场专利申请趋势

为何购买此报告？

  • 本报告提供全面的市场分析，并针对整体市场和特定细分市场提供详细的收入预测。这些资讯对于现有的市场领导者和新进入者都极具价值。
  • 利害关係人可以利用本报告深入了解市场竞争动态。透过分析竞争格局，企业可以做出明智的决策，优化市场定位并制定有效的市场进入策略。
  • 本报告为利害关係人提供了全面的市场概览，包括关键推动因素、阻碍因素和挑战。这些资讯使利害关係人能够掌握市场趋势，并做出基于数据的决策，从而掌握成长前景。

更多优势

  • 免费 Excel 资料包
  • 10% 免费内容客製化
  • 研究团队提供详细的报告讲解
  • 如果报告超过 6-12 个月，可免费更新报告

本报告提供全球稀少肾臟疾病市场相关调查，提供市场概要，以及各标的适应症，各分子类型，生技药品类别，各给药途径，治疗类别，主要各地区，主要医药品开发各企业趋势，及加入此市场的主要企业简介等资讯。

目录

章节I:报告概要

第1章 背景

第2章 调查手法

第3章 市场动态

第4章 宏观经济指标

章节II:定性性的洞察

第5章 摘要整理

第6章 简介

  • 肾臟疾病概要
  • 稀少肾臟疾病治疗目标的选择
  • 稀少肾臟疾病领域的技术的进步
  • 稀少肾臟疾病领域的最近的趋势
  • 未来展望

章节III:竞争情形

第7章 市场形势

第8章 企业竞争力分析

章节VI:企业简介

第9章 稀少肾臟疾病市场:北美为据点的医药品·开发治疗企业的企业简介

  • 章概要
  • Alexion Pharmaceuticals
  • Biogen
  • NovelMed
  • Travere Therapeutics
  • Vertex Pharmaceuticals
  • Amgen
  • Vera Therapeutics
  • ZyVersa Therapeutics

第10章 稀少肾臟疾病市场:欧洲为据点的医药品·开发治疗企业的企业简介

  • 章概要
  • Novartis
  • Roche
  • Advicenne
  • Boehringer Ingelheim
  • Calliditas Therapeutics

第11章 稀少肾臟疾病市场:亚太地区为据点的医药品·开发治疗企业的企业简介

  • 章概要
  • Jiangsu Hengrui Pharmaceuticals
  • Asahi Kasei

章节V:市场趋势

第12章 伙伴关係和合作

  • 伙伴关係模式
  • 稀少肾臟疾病的药/治疗方法:伙伴关係联合

第13章 资金筹措与投资

  • 资金筹措模式
  • 资金筹措生命週期分析
  • 投资案例:风险与回本
  • 稀少肾臟疾病的药/治疗方法:资金筹措与投资
  • 投资摘要

第14章 临床试验分析

  • 调查手法主要的参数
  • 稀少肾臟疾病的药/治疗方法:临床试验分析

第15章 临床性商业性魅力

  • 调查手法主要的参数
  • 评分
  • 把稀少肾臟疾病作为标的第三阶段的药物/治疗方法

第16章 主要意见领袖

第17章 稀少肾臟疾病市场:案例研究

与章节VI:市场预测机会分析

第18章 市场影响分析:促进因素，阻碍因素，机会，课题

  • 章概要
  • 市场促进因素
  • 市场阻碍因素
  • 市场机会
  • 市场课题
  • 结论

第19章 稀少肾臟疾病市场

  • 主要的前提调查手法
  • 全球稀少肾臟疾病市场:历史的趋势与2040年为止的预测
  • 主要的市场区隔

第20章 稀少肾臟疾病市场(各标的适应症)

第21章 稀少肾臟疾病市场(各分子类型)

第22章 稀少肾臟疾病市场(生物製药类别)

第23章 稀少肾臟疾病市场(各给药途径)

第24章 稀少肾臟疾病市场(治疗类别)

第25章 稀少肾臟疾病市场(主要各地区)

第26章 稀少肾臟疾病市场，医药品的销售额预测

第27章 稀少肾臟疾病市场(主要医药品开发各企业)

章节VII:其他的垄断的洞察

第28章 结论

第29章 来自1次调查的洞察

章节VIII:附录

第30章 表格形式资料

第31章 企业·团体一览

Product Code: RA100484

RARE KIDNEY DISEASES MARKET

As per Roots Analysis, the global rare kidney diseases market size is valued at USD 2.2 billion in 2024 and is projected to reach USD 2.8 billion in the current year and USD 11. 6 billion by 2035, growing at a CAGR of 15.2% during the forecast period.

The opportunity for rare kidney diseases market has been distributed across the following segments:

Target Disease Indications

  • Atypical Hemolytic Uremic Syndrome
  • Fabry Disease
  • Focal Segmental Glomerulosclerosis
  • Immunoglobulin A Nephropathy
  • Lupus Nephritis
  • Others

Type of Molecule

  • Biologics
  • Small Molecules

Type of Biologic

  • Enzymes
  • Hormones
  • Monoclonal Antibodies
  • Proteins

Route of Administration

  • Intravenous
  • Oral
  • Subcutaneous

Type of Therapy

  • Monotherapy
  • Combination Therapy

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific

RARE KIDNEY DISEASES MARKET: GROWTH AND TRENDS

Kidney diseases include a wide array of conditions that hinder the natural ability of the kidney to efficiently filter waste and excess fluid from the blood. These diseases also compromise the overall function of the kidneys to regulate blood pressure and maintain the overall fluid balance in the body. Notably, in the early stages, kidney diseases often present no symptoms, making the diagnosis challenging. However, as waste accumulates in the body, patients may experience symptoms, such as high blood pressure, anemia, poor nutritional health and nerve damage. According to the US Centers for Disease Control and Prevention, approximately 35.5 million people in the US were estimated to be affected by kidney diseases, in 2024, accounting for nearly 14% of the overall population. A subset of these conditions, rare kidney diseases, affect a smaller fraction of individuals worldwide. Under the Orphan Drug Act, a disease is classified as rare in the US if it affects less than 200,000 people. However, in the European Union, rare diseases are defined as those impacting around 5 per 10,000 Europeans.

Rare kidney diseases primarily affect the kidneys' filtering units (known as glomeruli), leading to the spillage of protein components and blood into the urine. These conditions can either be congenital, acquired or inherited, making it difficult to identify specific biomarkers for diagnosis and treatment. Without timely intervention, rare kidney diseases often lead to kidney failure, necessitating dialysis or transplantation. It is important to mention that kidney failure due to a rare chronic kidney disease has been observed in at least 3 out of 5 children and 1 in 9 adults suffering from kidney diseases. To address these challenges, significant advancements have been made in diagnosing and treating rare kidney diseases. Precision medicines, including genomic sequencing and personalized therapies, have enabled the targeted treatment of these diseases. Additionally, the integration of big data and machine learning has helped several drug developers and researchers by improving patient recruitment for clinical trials and identifying accurate urinary biomarkers for tailored treatment.

Rare Kidney Diseases Market - IMG1

Moreover, substantial investment from both public and private sectors accelerates research and development in this domain. Presently, drug developers have secured over USD 12 billion in funding for rare kidney research and treatment development. Further, with a growing focus on efficient diagnosis and treatment, the market for rare kidney disease drugs / therapies is poised for robust growth, presenting significant opportunities for stakeholders in the coming years.

RARE KIDNEY DISEASES MARKET: KEY INSIGHTS

The report delves into the current state of the rare kidney diseases market and identifies potential growth opportunities within the industry. Some key findings from the report include:

  • Over 70% of the rare kidney drugs / therapies are in clinical stages of development; notably, most of the drugs / therapies are being investigated for the treatment of immunoglobulin A nephropathy and lupus nephritis.
Rare Kidney Diseases Market - IMG2
  • The rising interest in this domain is evident from the wide array of partnerships established between various stakeholders in the recent past; in fact, 65% of the total deals were inked in the last three years.
  • Several investors, having realized the opportunity within this domain, have invested significant capital across various funding rounds; 45% of the investments in this domain were made through secondary offerings.
  • Nearly 40% of the drugs targeting rare kidney diseases are currently in Phase II of clinical development; notably, around 60% of the trials have been sponsored by industry players.
Rare Kidney Diseases Market - IMG3
  • The rare kidney disease market is likely to grow at an annualized rate (CAGR) of ~15%, till 2035; the majority of the market share (~70%) is expected to be captured by North America, by 2035.
Rare Kidney Diseases Market - IMG4
  • Currently, the monoclonal antibodies dominate the market; notably, oral route of administration is anticipated to capture the majority share in the market by 2035.

RARE KIDNEY DISEASES MARKET: KEY SEGMENTS

Lupus Nephritis is the Fastest Growing Segment in the Rare Kidney Diseases Market

Based on the type of target disease indication, the global rare kidney disease market is segmented into atypical hemolytic uremic syndrome, Fabry disease, focal segmental glomerulosclerosis, immunoglobulin A nephropathy, lupus nephritis, and others. Currently, the majority share of the rare kidney disease market is captured by lupus nephritis, due to the increasing awareness regarding the adversity of the disease among both patient population and healthcare professionals.

Small Molecules are Likely to Hold the Largest Share of the Rare Kidney Diseases Market During the Forecast Period

Based on the type of molecule, the global market is segmented into small molecules and biologics. Amongst these types, the small molecules segment occupies the largest share of the current overall market. However, it is important to note that biologics are expected to emerge as a promising alternative that can target underlying biological pathways associated with rare kidney disease, therefore, capturing a larger market share in the coming years.

Rare Kidney Diseases Market for Proteins is Likely to Grow at a Relatively Faster Pace During the Forecast Period

Based on the type of biologic, the global market value is segmented across enzymes, hormones, monoclonal antibodies, and proteins. Notably, the monoclonal antibodies segment dominates the current market. Moreover, this trend is unlikely to change in the foreseen future owing to their proven precision in treating rare kidney diseases.

Oral Route of Administration Holds the Largest Share of the Rare Kidney Diseases Market

Based on the route of administration, the global market is segmented across intravenous, oral and subcutaneous routes of administration. Currently, the oral route is expected to hold the majority rare kidney disease market share owing to its non-invasive nature and increased patient compliance as compared to other routes. However, it is worth mentioning that this trend is expected to change during the forecast period, with the subcutaneous route of administration capturing a larger share of the overall market in the coming years.

By Type of Therapy, Monotherapy Segment is Likely to Dominate the Market During the Forecast Period

Based on the type of therapy, the global market for rare kidney diseases is segmented across monotherapy and combination therapy. At present, the monotherapy segment holds the maximum share in the overall market. However, the market for combination therapy is likely to grow at a relatively higher CAGR during the forecast period.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific. In the current scenario, North America is likely to capture the largest market share. However, the market in Asia-Pacific is expected to grow at a faster pace during the forecast period owing to the fact that various Asian countries, such as China, Japan, Korea, and India are reporting increasing incidence rates of rare kidney diseases which necessitates more effective treatment management systems in this region.

Example Players in the Rare Kidney Diseases Market

  • Alexion Pharmaceuticals
  • Amicus Therapeutics
  • Apellis Pharmaceuticals
  • Aurinia Pharmaceuticals
  • GlaxoSmithKline
  • Novartis
  • Roche
  • Travere Therapeutics
  • Vera Therapeutics

RARE KIDNEY DISEASES MARKET: RESEARCH COVERAGE

The report on Rare Kidney Diseases Market features insights into various sections, including:

  • Market Sizing and Opportunity Analysis: An in-depth analysis of the rare kidney diseases market, focusing on key market segments, including [A] type of disease indication, [B] type of molecule, [C] type of biologic, [D] route of administration, [E] type of therapy, [F] key geographical regions, and [G] key players.
  • Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.
  • Market Landscape: A comprehensive evaluation of rare kidney diseases drugs / therapies developers, based on several relevant parameters, such as [A] stage of development, [B] target indication, [C] route of administration, [D] type of molecule, [E] type of biologic, [F] dosing frequency, [G] target patient population, and [H] type of therapy.
  • Rare Kidney Diseases Drug / Therapies Developer Landscape: The report features a list of leading players engaged in the rare kidney diseases domain, along with analyses based on [A] year of establishment, [B] company size, [C] location of headquarters, and [D] most active players (in terms of number of drugs / therapies developed).
  • Company Competitiveness Analysis: An insightful competitiveness analysis of the companies engaged in the rare kidney diseases domain, based on various relevant parameters, such as [A] company strength, [B] portfolio strength, and [C] pipeline diversity.
  • Company Profiles: In-depth profiles of key industry players offering rare kidney drugs / therapies across various geographies, focusing on [A] company overviews, [B] drug portfolio, [C] financial information (if available), [D] recent developments and [E] an informed future outlook.
  • Partnerships and Collaborations: A detailed analysis of partnerships inked between stakeholders in the rare kidney diseases market, since 2019, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] target disease indication, [D] type of partner, [E] most active players (in terms of number of partnerships), and [F] geography.
  • Funding and Investments Analysis: A detailed analysis of the various funding and investments raised in the rare kidney diseases domain, based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount of funding, [D] target disease indication, [E] geography, and [F] most active players (in terms of number of funding instances).
  • Clinical Trial Analysis: An in-depth analysis of completed / ongoing clinical trials related to rare kidney diseases drugs / therapies, based on various relevant parameters, such as [A] trial registration year, [B] trial status, [C] number of patients enrolled, [D] trial phase, [E] study design (type of trial masking, type of intervention model, trial purpose and design allocation), [F] type of sponsor, [G] patient gender, [H] most active sponsor / collaborator (leading industry and non-industry players based on the number of registered trials), and [I] geography.
  • Clinical Commercial Attractiveness: A detailed analysis of the clinical and commercial attractiveness for phase III drugs / therapies targeting rare kidney diseases, based on several parameters, such as [A] type of molecule, [B] dosing frequency, [C] route of administration, [D] number of patients enrolled, [E] company size, [F] patient population, and [G] location of clinical trials.
  • KOL Analysis: An insightful analysis, highlighting the key opinion leaders investigating the clinical trials related to rare kidney diseases, based on several parameters, such as [A] type of KOL, [B] qualification, [C] type of organization, [D] geographical location of KOLs, [E] target disease indication, and [F] most prominent KOLs (based on our proprietary and third-party scoring criteria).
  • Case Study: An insightful case study highlighting the developers engaged in offering kidney care services, along with information on [A] year of establishment, [B] company size, [C] location of headquarters, [D] target indications, [E] benefits offered by the kidney care companies, and [F] recent developments in the domain.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What is the patent filing activity trend in the market?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary Excel Data Packs
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

SECTION I: REPORT OVERVIEW

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Overview of Kidney Diseases
    • 6.1.1. Key Historical Events related to Kidney Diseases
    • 6.1.2. Factors Contributing to the Onset of Kidney Diseases
  • 6.2. Selection of Therapeutic Targets for Rare Kidney Diseases
  • 6.3. Technological Advancements in the Rare Kidney Diseases Domain
  • 6.4. Recent Developments in the Rare Kidney Diseases Domain
  • 6.5. Future Perspectives

SECTION III: COMPETITIVE LANDSCAPE

7. MARKET LANDSCAPE

  • 7.1. Rare Kidney Disease Drugs / Therapies: Market Landscape
    • 7.1.1. Analysis by Stage of Development
    • 7.1.2. Analysis by Target Indication
    • 7.1.3. Analysis by Route of Administration
    • 7.1.4. Analysis by Type of Molecule
    • 7.1.5. Analysis by Type of Biologic
    • 7.1.6. Analysis by Dosing Frequency
    • 7.1.7. Analysis by Target Patient Population
    • 7.1.8. Analysis by Type of Therapy
  • 7.2. Rare Kidney Disease Drugs / Therapies: Developer Landscape
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Location of Headquarters
    • 7.2.4. Analysis by Company Size and Location of Headquarters
    • 7.2.5. Most Active Players: Analysis by Number of Drugs / Therapies Developed

8. COMPANY COMPETITIVENESS ANALYSIS

  • 8.1 Methodology and Key Parameters
  • 8.2. Scoring
  • 8.3. Peer Groups
    • 8.3.1. Overview of Developers based in North America
      • 8.3.1.1. Competitiveness Analysis of Players based in North America
      • 8.3.1.2. Leading Players based in North America
    • 8.3.2. Overview of Developers based in Europe
      • 8.3.2.1. Competitiveness Analysis of Players based in Europe
      • 8.3.2.2. Leading Players based in Europe
    • 8.3.3. Overview of Developers based in Asia-Pacific and Rest of the World
      • 8.3.3.1. Competitiveness Analysis of Players based in Asia-Pacific and Rest of the World
      • 8.3.3.2. Leading Players based in Asia-Pacific and Rest of the World

SECTION IV: COMPANY PROFILES

9. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY DEVELOPERS BASED IN NORTH AMERICA

  • 9.1. Chapter Overview
  • 9.2. Alexion Pharmaceuticals
    • 9.2.1. Company Details
    • 9.2.2. Drug Portfolio
    • 9.2.3. Financial Details
    • 9.2.4. Recent Developments and Future Outlook
  • 9.3. Biogen
    • 9.3.1. Company Details
    • 9.3.2. Drug Portfolio
    • 9.3.3. Financial Details
    • 9.3.4. Recent Developments and Future Outlook
  • 9.4. NovelMed
    • 9.4.1. Company Details
    • 9.4.2. Drug Portfolio
    • 9.4.3. Recent Developments and Future Outlook
  • 9.5. Travere Therapeutics
    • 9.5.1. Company Details
    • 9.5.2. Drug Portfolio
    • 9.5.3. Financial Details
    • 9.5.4. Recent Developments and Future Outlook
  • 9.6. Vertex Pharmaceuticals
    • 9.6.1. Company Details
    • 9.6.2. Drug Portfolio
    • 9.6.3. Financial Details
    • 9.6.4. Recent Developments and Future Outlook
  • 9.7. Amgen
    • 9.7.1. Company Details
    • 9.7.2. Drug Portfolio
  • 9.8. Vera Therapeutics
    • 9.8.1. Company Details
    • 9.8.2. Drug Portfolio
  • 9.9. ZyVersa Therapeutics
    • 9.9.1. Company Details
    • 9.9.2. Drug Portfolio

10. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY DEVELOPERS BASED IN EUROPE

  • 10.1. Chapter Overview
  • 10.2. Novartis
    • 10.2.1. Company Details
    • 10.2.2. Drug Portfolio
    • 10.2.3. Financial Details
    • 10.2.4. Recent Developments and Future Outlook
  • 10.3. Roche
    • 10.3.1. Company Details
    • 10.3.2. Drug Portfolio
    • 10.3.3. Financial Details
    • 10.3.4. Recent Developments and Future Outlook
  • 10.4. Advicenne
    • 10.4.1. Company Details
    • 10.4.2. Drug Portfolio
  • 10.5. Boehringer Ingelheim
    • 10.5.1. Company Details
    • 10.5.2. Drug Portfolio
  • 10.6. Calliditas Therapeutics
    • 10.6.1. Company Details
    • 10.6.2. Drug Portfolio

11. RARE KIDNEY DISEASE MARKET: COMPANY PROFILES OF DRUG / THERAPY DEVELOPERS BASED IN ASIA-PACIFIC

  • 11.1. Chapter Overview
  • 11.2. Jiangsu Hengrui Pharmaceuticals
    • 11.2.1. Company Details
    • 11.2.2. Drug Portfolio
    • 11.2.3. Recent Developments and Future Outlook
  • 11.2. Asahi Kasei
    • 11.2.1. Company Details
    • 11.2.2. Drug Portfolio

SECTION V: MARKET TRENDS

12. PARTNERSHIPS AND COLLABORATIONS

  • 12.1. Partnership Models
  • 12.2. Rare Kidney Disease Drugs / Therapies: Partnerships and Collaborations
    • 12.2.1. Analysis by Year of Partnership
    • 12.2.2. Analysis by Type of Partnership
    • 12.2.3. Analysis by Year and Type of Partnership
    • 12.2.4. Analysis by Target Disease Indication
    • 12.2.5. Analysis by Type of Partner
    • 12.2.6. Most Active Players: Analysis by Number of Partnerships
    • 12.2.7. Local and International Deals
    • 12.2.8. Intercontinental and Intracontinental Deals

13. FUNDING AND INVESTMENTS

  • 13.1. Funding Models
  • 13.2. Funding Lifecycle Analysis
  • 13.3. Investment Case: Risk and Return
  • 13.4. Rare Kidney Disease Drugs / Therapies: Funding and Investments
    • 13.4.1. Analysis of Funding Instances by Year of Funding
    • 13.4.2. Analysis of Funding Instances by Type of Funding
    • 13.4.3. Analysis of Funding Instances by Year and Type of Funding
    • 13.4.4. Analysis of Amount Invested by Year of Funding
    • 13.4.5. Analysis of Amount Invested by Type of Funding
    • 13.4.6. Analysis of Amount Invested by Year and Type of Funding
    • 13.4.7. Analysis of Funding Instances by Target Disease Indication
    • 13.4.8. Analysis of Funding Instances by Geography (Region)
    • 13.4.9. Analysis of Funding Instances by Geography (Country)
    • 13.4.10. Most Active Players: Analysis by Number of Funding Instances
    • 13.4.11. Most Active Players: Analysis by Amount Invested
    • 13.4.12. Leading Investors: Analysis by Number of Funding Instances
  • 13.5. Summary of Investments

14. CLINICAL TRIAL ANALYSIS

  • 14.1. Methodology and Key Parameters
  • 14.2. Rare Kidney Disease Drugs / Therapies: Clinical Trial Analysis
    • 14.2.1. Analysis by Trial Registration Year
    • 14.2.2. Analysis by Trial Status
    • 14.2.3. Analysis by Trial Registration Year and Trial Status
    • 14.2.4. Analysis by Trial Registration Year and Patients Enrolled
    • 14.2.5. Analysis by Trial Status and Patients Enrolled
    • 14.2.6. Analysis by Trial Phase
    • 14.2.7. Analysis by Patients Enrolled and Trial Phase
    • 14.2.8. Analysis by Study Design
    • 14.2.9. Analysis by Type of Sponsor
    • 14.2.10. Analysis by Patient Gender
    • 14.2.11. Most Active Industry Players: Analysis by Number of Trials
    • 14.2.12. Most Active Non-Industry Players: Analysis by Number of Trials
    • 14.2.13. Analysis by Geography
      • 14.2.13.1. Analysis by Trial Status, Trial Phase and Geography
      • 14.2.13.2. Analysis by Trial Status and Geography
    • 14.2.14. Geographical Distribution of Trials and Number of Patients Enrolled
      • 14.2.14.1. Clinical Trials in North America: Key Insights
      • 14.2.14.2. Clinical Trials in Europe: Key Insights
      • 14.2.14.3. Clinical Trials in Asia-Pacific: Key Insights
      • 14.2.14.4. Clinical Trials in Rest of the World: Key Insights

15. CLINICAL COMMERCIAL ATTRACTIVENESS

  • 15.1. Methodology and Key Parameters
  • 15.2. Scoring
  • 15.3. Phase III Drugs / Therapies Targeting Rare Kidney Diseases

16. KEY OPINION LEADERS

  • 16.1. Methodology and Key Parameters
  • 16.2. Rare Kidney Disease Drugs / Therapies: Key Opinion Leaders
    • 16.2.1. Analysis by Type of Key Opinion Leader
    • 16.2.2. Analysis by Qualification
    • 16.2.3. Analysis by Type of Organization
    • 16.2.4. Analysis by Target Disease Indication
    • 16.2.5. Analysis by Region of Key Opinion Leaders
  • 16.3. Scoring Criteria
    • 16.3.1. Most Prominent Key Opinion Leaders
    • 16.3.2. Benchmarking: Roots Analysis' Assessment vs Third Party Scores

17. RARE KIDNEY DISEASE MARKET: CASE STUDY

  • 17.1. Methodology
  • 17.2. Rare Kidney Disease Market: List of Kidney Care Companies
  • 17.3. Benefits Offered by Kidney Care Companies
  • 17.4. Recent Developments

SECTION VI: MARKET FORECAST AND OPPORTUNITY ANALYSIS

18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 18.1. Chapter Overview
  • 18.2. Market Drivers
  • 18.3. Market Restraints
  • 18.4. Market Opportunities
  • 18.5. Market Challenges
  • 18.6. Conclusion

19. RARE KIDNEY DISEASE MARKET

  • 19.1. Key Assumptions and Methodology
  • 19.2. Global Rare Kidney Disease Market: Historical Trends and Forecasted Estimates, till 2040
    • 19.2.1. Comparison with Previous Edition
    • 19.2.2. Multivariate Scenario Analysis
      • 19.2.2.1. Conservative Scenario
      • 19.2.2.2. Optimistic Scenario
  • 19.3. Key Market Segmentations

20. RARE KIDNEY DISEASE MARKET, BY TARGET DISEASE INDICATION

  • 20.1. Rare Kidney Disease Market: Distribution by Target Disease Indication
    • 20.1.1. Rare Kidney Disease Market for Lupus Nephritis: Historical Trends and Forecasted Estimates, till 2040
    • 20.1.2. Rare Kidney Disease Market for Immunoglobulin A Nephropathy: Historical Trends and Forecasted Estimates, till 2040
    • 20.1.3. Rare Kidney Disease Market for Fabry Disease: Historical Trends and Forecasted Estimates, till 2040
    • 20.1.4. Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome: Historical Trends and Forecasted Estimates, till 2040
    • 20.1.5. Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis: Historical Trends and Forecasted Estimates, till 2040
    • 20.1.6. Rare Kidney Disease Market for Others: Historical Trends and Forecasted Estimates, till 2040

21. RARE KIDNEY DISEASE MARKET, BY TYPE OF MOLECULE

  • 21.1. Rare Kidney Disease Market: Distribution by Type of Molecule
    • 21.1.1. Rare Kidney Disease Market for Small Molecules: Historical Trends and Forecasted Estimates, till 2040
    • 21.1.2. Rare Kidney Disease Market for Biologics: Historical Trends and Forecasted Estimates, till 2040

22. RARE KIDNEY DISEASE MARKET, BY TYPE OF BIOLOGIC

  • 22.1. Rare Kidney Disease Market: Distribution by Type of Biologic
    • 22.1.1. Rare Kidney Disease Market for Monoclonal Antibodies: Historical Trends and Forecasted Estimates, till 2040
    • 22.1.2. Rare Kidney Disease Market for Enzymes: Historical Trends and Forecasted Estimates, till 2040
    • 22.1.3. Rare Kidney Disease Market for Proteins: Historical Trends and Forecasted Estimates, till 2040
    • 22.1.4. Rare Kidney Disease Market for Hormones: Historical Trends and Forecasted Estimates, till 2040

23. RARE KIDNEY DISEASE MARKET, BY ROUTE OF ADMINISTRATION

  • 23.1. Rare Kidney Disease Market: Distribution by Route of Administration
    • 23.1.1. Rare Kidney Disease Market for Oral Route: Historical Trends and Forecasted Estimates, till 2040
    • 23.1.2. Rare Kidney Disease Market for Intravenous Route: Historical Trends and Forecasted Estimates, till 2040
    • 23.1.3. Rare Kidney Disease Market for Subcutaneous Route: Historical Trends and Forecasted Estimates, till 2040

24. RARE KIDNEY DISEASE MARKET, BY TYPE OF THERAPY

  • 24.1. Rare Kidney Disease Market: Distribution by Type of Therapy
    • 24.1.1. Rare Kidney Disease Market for Monotherapy: Historical Trends and Forecasted Estimates, till 2040
    • 24.1.2. Rare Kidney Disease Market for Combination Therapy: Historical Trends and Forecasted Estimates, till 2040

25. RARE KIDNEY DISEASE MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 25.1. Rare Kidney Disease Market: Distribution by Key Geographical Regions
    • 25.1.1. Rare Kidney Disease Market in North America: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.1.1. Rare Kidney Disease Market in the US: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.1.2. Rare Kidney Disease Market in Canada: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.2. Rare Kidney Disease Market in Europe: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.2.1. Rare Kidney Disease Market in Germany: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.2.2. Rare Kidney Disease Market in UK: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.2.3. Rare Kidney Disease Market in Spain: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.2.4. Rare Kidney Disease Market in France: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.2.5. Rare Kidney Disease Market in the Italy: Historical Trends and Forecasted Estimates, till 2040
    • 25.1.3. Rare Kidney Disease Market in Asia-Pacific: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.3.1. Rare Kidney Disease Market in China: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.3.2. Rare Kidney Disease Market in India: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.3.3. Rare Kidney Disease Market in South Korea: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.3.4. Rare Kidney Disease Market in Japan: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.3.5. Rare Kidney Disease Market in Australia: Historical Trends and Forecasted Estimates, till 2040
      • 25.1.3.6. Rare Kidney Disease Market in Taiwan: Historical Trends and Forecasted Estimates, till 2040

26. RARE KIDNEY DISEASE MARKET, SALES FORECAST OF DRUGS

  • 26.1. Approved Rare Kidney Disease Drugs / Therapies: Sales Forecast
    • 26.1.1. Benlysta(R): Sales Forecast
    • 26.1.2. Elfabrio(R): Sales Forecast
    • 26.1.3. FILSPARI(R): Sales Forecast
    • 26.1.4. Galafold(R): Sales Forecast
    • 26.1.5. LUPKYNIS(R): Sales Forecast
    • 26.1.6. Sibnayal(R): Sales Forecast
    • 26.1.7. Tarpeyo(R): Sales Forecast
    • 26.1.8. TERLIVAZ(R): Sales Forecast
    • 26.1.9. ULTOMIRIS(R): Sales Forecast
  • 26.2. Phase III Rare Kidney Disease Drugs / Therapies: Sales Forecast
    • 26.2.1. ALPN-303 (Immunoglobulin A Nephropathy): Sales Forecast
    • 26.2.2. APL-2 (C3 Glomerulopathy): Sales Forecast
    • 26.2.3. APL-2 (Membranous Nephropathy): Sales Forecast
    • 26.2.4. Atacicept (Immunoglobulin A Nephropathy): Sales Forecast
    • 26.2.5. Atacicept (Lupus Nephritis): Sales Forecast
    • 26.2.6. Atrasentan (Immunoglobulin A Nephropathy): Sales Forecast
    • 26.2.7. Crovalimab (Atypical Hemolytic Uremic Syndrome): Sales Forecast
    • 26.2.8. FILSPARI(R) (Focal Segmental Glomerulosclerosis): Sales Forecast
    • 26.2.9. Ianalumab (Lupus Nephritis): Sales Forecast
    • 26.2.10. Iptacopan (Atypical Hemolytic Uremic Syndrome): Sales Forecast
    • 26.2.11. Iptacopan (C3 Glomerulopathy): Sales Forecast
    • 26.2.12. Iptacopan (Immunoglobulin A Nephropathy): Sales Forecast
    • 26.2.13. Lucerastat (Fabry Disease): Sales Forecast
    • 26.2.14. MIL62 (Membranous Nephropathy): Sales Forecast
    • 26.2.15. Obinutuzumab (Nephrotic Syndrome): Sales Forecast
    • 26.2.16. Obinutuzumab (Membranous Nephropathy): Sales Forecast
    • 26.2.17. Obinutuzumab (Lupus Nephritis): Sales Forecast
    • 26.2.18. Repagermanium (Focal Segmental Glomerulosclerosis): Sales Forecast
    • 26.2.19. Saphnelo(TM) (Lupus Nephritis): Sales Forecast
    • 26.2.20. Sibeprenlimab (Immunoglobulin A Nephropathy): Sales Forecast
    • 26.2.21. SNP-ACTH (Membranous Nephropathy): Sales Forecast
    • 26.2.22. Telitacicept (Immunoglobulin A Nephropathy): Sales Forecast
    • 26.2.23. Tolvaptan (Autosomal Recessive Polycystic Kidney Disease): Sales Forecast
    • 26.2.24. ULTOMIRIS(R) (Immunoglobulin A Nephropathy): Sales Forecast
    • 26.2.25. Venglustat (Fabry Disease): Sales Forecast
    • 26.2.26. Zigakibart (Immunoglobulin A Nephropathy): Sales Forecast

27. RARE KIDNEY DISEASE MARKET, BY LEADING DRUG DEVELOPERS

SECTION VII: OTHER EXCLUSIVE INSIGHTS

28. CONCLUDING INSIGHTS

29. INSIGHTS FROM PRIMARY RESEARCH

SECTION VIII: APPENDICES

30. TABULATED DATA

31. LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 List of Rare Kidney Disease Drugs / Therapies
  • Table 7.2 List of Rare Kidney Disease Drug / Therapy Developers
  • Table 9.1 Alexion Pharmaceuticals: Drug Portfolio
  • Table 9.2 Biogen: Drug Portfolio
  • Table 9.3 NovelMed: Drug Portfolio
  • Table 9.4 Travere Therapeutics: Drug Portfolio
  • Table 9.5 Vertex Pharmaceuticals: Drug Portfolio
  • Table 9.6 Amgen: Drug Portfolio
  • Table 9.7 Vera Therapeutics: Drug Portfolio
  • Table 9.8 ZyVersa Therapeutics: Drug Portfolio
  • Table 10.1 Novartis: Drug Portfolio
  • Table 10.2 Roche: Drug Portfolio
  • Table 10.3 Advicenne: Drug Portfolio
  • Table 10.4 Boehringer Ingelheim: Drug Portfolio
  • Table 10.5 Calliditas Therapeutics: Drug Portfolio
  • Table 11.1 Jiangsu Hengrui Pharmaceuticals: Drug Portfolio
  • Table 11.2 Asahi Kasei: Drug Portfolio
  • Table 12.1 Rare Kidney Disease Drugs / Therapies: List of Partnerships and Collaborations, since 2019
  • Table 13.1 Rare Kidney Disease Drugs / Therapies: List of Funding and Investments, since 2019
  • Table 14.1. Rare Kidney Disease Drugs / Therapies: List of Clinical Trials, since 2019
  • Table 16.1. Rare Kidney Disease Drugs / Therapies: List of Key Opinion Leaders
  • Table 17.1 Rare Kidney Disease Market: List of Kidney Care Companies
  • Table 19.1 Rare Kidney Disease Therapies: List of Forecasted Therapies
  • Table 30.1 Rare Kidney Disease Drugs / Therapies: Distribution by Stage of Development
  • Table 30.2 Rare Kidney Disease Drugs / Therapies: Distribution by Target Indication
  • Table 30.3 Rare Kidney Disease Drugs / Therapies: Distribution by Route of Administration
  • Table 30.4 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Molecule
  • Table 30.5 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Biologic
  • Table 30.6 Rare Kidney Disease Drugs / Therapies: Distribution by Dosing Frequency
  • Table 30.7 Rare Kidney Disease Drugs / Therapies: Distribution by Target Patient Population
  • Table 30.8 Rare Kidney Disease Drugs / Therapies: Distribution by Type of Therapy
  • Table 30.9 Rare Kidney Disease Drug / Therapy Developers: Distribution by Year of Establishment
  • Table 30.10 Rare Kidney Disease Drug / Therapy Developers: Distribution by Company Size
  • Table 30.11 Rare Kidney Disease Drug / Therapy Developers: Distribution by Location of Headquarters
  • Table 30.12 Rare Kidney Disease Drug / Therapy Developers: Distribution by Company Size and Location of Headquarters
  • Table 30.13 Most Active Players: Analysis by Number of Drugs / Therapies Developed
  • Table 30.14 Rare Kidney Disease Drug / Therapies Developers based in North America: Distribution by Company Size
  • Table 30.15 Rare Kidney Disease Drug / Therapies Developers based in North America: Distribution by Stage of Development
  • Table 30.16 Rare Kidney Disease Drug / Therapies Developers based in North America: Distribution by Type of Molecule
  • Table 30.17 Rare Kidney Disease Drug / Therapies Developers based in Europe: Distribution by Company Size
  • Table 30.18 Rare Kidney Disease Drug / Therapies Developers based in Europe: Distribution by Type of Molecule
  • Table 30.19 Rare Kidney Disease Drug / Therapies Developers based in Europe: Distribution by Route of Administration
  • Table 30.20 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Company Size
  • Table 30.21 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Stage of Development
  • Table 30.22 Rare Kidney Disease Drug / Therapies Developers based in Asia-Pacific and Rest of the World: Distribution by Type of Molecule
  • Table 30.23 Alexion Pharmaceuticals: Annual Revenues, since FY 2021 (USD Billion)
  • Table 30.24 Biogen: Annual Revenues, since FY 2021 (USD Billion)
  • Table 30.25 Travere Therapeutics: Annual Revenues, since FY 2021 (USD Million)
  • Table 30.26 Vertex Pharmaceuticals: Annual Revenues, since FY 2021 (USD Billion)
  • Table 30.27 Novartis: Annual Revenues, since FY 2021 (USD Billion)
  • Table 30.28 Roche: Annual Revenues, since FY 2021 (CHF Billion)
  • Table 30.29 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 30.30 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 30.31 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 30.32 Partnerships and Collaborations: Distribution by Target Disease Indication
  • Table 30.33 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 30.34 Most Active Players: Distribution by Number of Partnerships
  • Table 30.35 Partnerships and Collaborations: Local and International Deals
  • Table 30.36 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 30.37 Funding and Investments: Distribution of Funding Instances by Year of Funding
  • Table 30.38 Funding and Investments: Distribution of Funding Instances by Type of Funding
  • Table 30.39 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding
  • Table 30.40 Funding and Investments: Distribution of Amount Invested by Year of Funding
  • Table 30.41 Funding and Investments: Distribution of Amount Invested by Type of Funding
  • Table 30.42 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding
  • Table 30.43 Funding and Investments: Distribution of Funding Instances by Target Disease Indication
  • Table 30.44 Funding and Investments: Distribution of Funding Instances by Geography (Region)
  • Table 30.45 Funding and Investments: Distribution of Funding Instances by Geography (Country)
  • Table 30.46 Most Active Players: Distribution by Number of Instances
  • Table 30.47 Most Active Players: Distribution by Amount Invested
  • Table 30.48 Leading Investors: Distribution by Number of Funding Instances
  • Table 30.49 Funding and Investments: Summary
  • Table 30.50 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Table 30.51 Clinical Trial Analysis: Distribution by Trial Status
  • Table 30.52 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 30.53 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
  • Table 30.54 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
  • Table 30.55 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 30.56 Clinical Trial Analysis: Distribution by Patients Enrolled and Trial Phase
  • Table 30.57 Clinical Trial Analysis: Distribution by Study Design
  • Table 30.58 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 30.59 Clinical Trial Analysis: Distribution by Patient Gender
  • Table 30.60 Most Active Industry Players: Distribution by Number of Trials
  • Table 30.61 Most Active Non-Industry Players: Distribution by Number of Trials
  • Table 30.62 Distribution by Trial Status, Trial Phase and Geography
  • Table 30.63 Distribution of Clinical Trials by Trial Status and Geography
  • Table 30.64 Distribution of Patients Enrolled by Trial Status and Geography
  • Table 30.65 Clinical Trials in North America: Key Insights
  • Table 30.66 Clinical Trials in Europe: Key Insights
  • Table 30.67 Clinical Trials in Asia-Pacific: Key Insights
  • Table 30.68 Clinical Trials in Rest of the World: Key Insights
  • Table 30.69 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Type of KOL
  • Table 30.70 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Qualification
  • Table 30.71 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Type of Organization
  • Table 30.72 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Target Disease Indication
  • Table 30.73 Rare Kidney Disease Drugs / Therapies KOL Analysis: Distribution by Geographical Location
  • Table 30.74 Benchmarking: Roots Analysis' Assessment vs Third Party Scores
  • Table 30.75 Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2040 (USD Billion)
  • Table 30.76 Global Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2040: Conservative Scenario (USD Billion)
  • Table 30.77 Global Rare Kidney Disease Market, Historical Trends and Forecasted Estimates, till 2040: Optimistic Scenario (USD Billion)
  • Table 30.78 Rare Kidney Disease Market: Distribution by Target Disease Indication
  • Table 30.79 Rare Kidney Disease Market for Lupus Nephritis: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.80 Rare Kidney Disease Market for Immunoglobulin A Nephropathy: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.81 Rare Kidney Disease Market for Fabry Disease: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.82 Rare Kidney Disease Market for Atypical Hemolytic Uremic Syndrome: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.83 Rare Kidney Disease Market for Focal Segmental Glomerulosclerosis: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.84 Rare Kidney Disease Market for Others: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.85 Rare Kidney Disease Market: Distribution by Type of Molecule
  • Table 30.86 Rare Kidney Disease Market for Small Molecules: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.87 Rare Kidney Disease Market for Biologics: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.88 Rare Kidney Disease Market: Distribution by Type of Biologic
  • Table 30.89 Rare Kidney Disease Market for Monoclonal Antibodies: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.90 Rare Kidney Disease Market for Enzymes: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.91 Rare Kidney Disease Market for Proteins: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.92 Rare Kidney Disease Market for Hormones: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.93 Rare Kidney Disease Market: Distribution by Route of Administration
  • Table 30.94 Rare Kidney Disease Market for Oral Route: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.95 Rare Kidney Disease Market for Intravenous Route: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.96 Rare Kidney Disease Market for Subcutaneous Route: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.97 Rare Kidney Disease Market: Distribution by Type of Therapy
  • Table 30.98 Rare Kidney Disease Market for Monotherapy: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.99 Rare Kidney Disease Market for Combination Therapy: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.100 Rare Kidney Disease Market: Distribution by Key Geographical Regions
  • Table 30.101 Rare Kidney Disease Market in North America: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.102 Rare Kidney Disease Market in the US: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.103 Rare Kidney Disease Market in Canada: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.104 Rare Kidney Disease Market in Europe: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.105 Rare Kidney Disease Market in Germany: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.106 Rare Kidney Disease Market in UK: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.107 Rare Kidney Disease Market in Spain: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.108 Rare Kidney Disease Market in France: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.109 Rare Kidney Disease Market in Italy: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.110 Rare Kidney Disease Market in Asia-Pacific: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.111 Rare Kidney Disease Market in China: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.112 Rare Kidney Disease Market in India: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.113 Rare Kidney Disease Market in South Korea: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.114 Rare Kidney Disease Market in Japan: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.115 Rare Kidney Disease Market in Australia: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.116 Rare Kidney Disease Market in Taiwan: Historical Trends and Forecasted Estimates, till 2040 (USD Million)
  • Table 30.117 Benlysta(R) (Lupus Nephritis): Sales Forecast (USD Million)
  • Table 30.118 Elfabrio(R) (Fabry Disease): Sales Forecast (USD Million)
  • Table 30.119 FILSPARI(R) (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.120 FABHALTA(R) (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.121 Galafold(R) (Fabry Disease): Sales Forecast (USD Million)
  • Table 30.122 LUPKYNIS(R) (Lupus Nephritis): Sales Forecast (USD Million)
  • Table 30.123 Sibnayal(R) (Distal Renal Tubular Acidosis): Sales Forecast (USD Million)
  • Table 30.124 Tarpeyo(R) (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.125 TERLIVAZ(R) (Hepatorenal Syndrome): Sales Forecast (USD Million)
  • Table 30.126 ULTOMIRIS(R) (Atypical Hemolytic Uremic Syndrome): Sales Forecast (USD Million)
  • Table 30.127 ALPN-303 (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.128 APL-2 (C3 Glomerulopathy): Sales Forecast (USD Million)
  • Table 30.129 APL-2 (Membranous Nephropathy): Sales Forecast (USD Million)
  • Table 30.130 Atacicept (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.131 Atacicept (Lupus Nephritis): Sales Forecast (USD Million)
  • Table 30.132 Atrasentan (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.133 Crovalimab (Atypical Hemolytic Uremic Syndrome): Sales Forecast (USD Million)
  • Table 30.134 FILSPARI(R) (Focal Segmental Glomerulosclerosis): Sales Forecast (USD Million)
  • Table 30.135 Ianalumab (Lupus Nephritis): Sales Forecast (USD Million)
  • Table 30.136 Iptacopan (Atypical Hemolytic Uremic Syndrome): Sales Forecast (USD Million)
  • Table 30.137 Iptacopan (C3 Glomerulopathy): Sales Forecast (USD Million)
  • Table 30.138 Lucerastat (Fabry Disease): Sales Forecast (USD Million)
  • Table 30.139 MIL62 (Membranous Nephropathy): Sales Forecast (USD Million)
  • Table 30.140 Obinutuzumab (Nephrotic Syndrome): Sales Forecast (USD Million)
  • Table 30.141 Obinutuzumab (Membranous Nephropathy): Sales Forecast (USD Million)
  • Table 30.142 Obinutuzumab (Lupus Nephritis): Sales Forecast (USD Million)
  • Table 30.143 Repagermanium (Focal Segmental Glomerulosclerosis): Sales Forecast (USD Million)
  • Table 30.144 Saphnelo(TM) (Lupus Nephritis): Sales Forecast (USD Million)
  • Table 30.145 Sibeprenlimab (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.146 SNP-ACTH (Membranous Nephropathy): Sales Forecast (USD Million)
  • Table 30.147 Telitacicept (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.148 Tolvaptan (Autosomal Recessive Polycystic Kidney Disease): Sales Forecast (USD Million)
  • Table 30.149 ULTOMIRIS(R) (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.150 Venglustat (Fabry Disease): Sales Forecast (USD Million)
  • Table 30.151 Zigakibart (Immunoglobulin A Nephropathy): Sales Forecast (USD Million)
  • Table 30.152 Rare Kidney Disease Market: Distribution by Leading Players, 2025 (based on revenues generated) (USD Billion)
  • Table 30.153 Rare Kidney Disease Market: Distribution by Leading Players, 2035 (based on revenues generated) (USD Billion)